Tags

Type your tag names separated by a space and hit enter

Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.
Ultrasound Obstet Gynecol. 2012 Mar; 39(3):341-7.UO

Abstract

OBJECTIVE

To evaluate whether the presence of polycystic ovary syndrome (PCOS) alters multiple ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women without any other health condition that could interfere with combined oral contraceptive (COC) eligibility criteria.

METHODS

This was a case-control study evaluating 90 obese women (body mass index (BMI) ≥ 30.0 kg/m(2) and < 40 kg/m(2)) aged between 18 and 40 years without any other health condition that could interfere with COC eligibility criteria, of whom 45 had PCOS and 45 were age-matched controls. BMI, waist and hip circumference, arterial blood pressure, fasting insulin and glucose, quantitative insulin sensitivity check index (QUICKI), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglycerides, testosterone, sex hormone-binding globulin, free androgen index (FAI), carotid stiffness index, intima media thickness, flow-mediated dilatation (FMD) of the brachial artery and non-alcoholic fatty liver disease (NAFLD) were assessed.

RESULTS

In women with PCOS, we observed a higher frequency of NAFLD (73.3 vs. 46.7%, P < 0.01) and higher FAI (10.4 vs. 6.8%, P < 0.01). We also observed a trend towards increased insulin levels (10.06 ± 6.66 vs. 7.45 ± 5.88 µIU/mL, P = 0.05), decreased QUICKI (0.36 ± 0.06 vs. 0.39 ± 0.07, P = 0.05) and decreased FMD (7.00 ± 3.87 vs. 8.41 ± 3.79%, P = 0.08). No other significant difference was observed.

CONCLUSIONS

NAFLD is frequent in obese women without any other health condition that could interfere with COC eligibility criteria, especially in those with PCOS. This should be considered when choosing the best contraceptive option.

Links

Aggregator Full Text

Authors+Show Affiliations

Zueff LF
Departamento de Ginecologia e Obstetrícia da Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil.
Martins WP
No affiliation info available
Vieira CS
No affiliation info available
Ferriani RA
No affiliation info available

MeSH

AdolescentAdultBiomarkersBlood GlucoseBody Mass IndexCardiovascular DiseasesCarotid Intima-Media ThicknessCase-Control StudiesCholesterol, HDLCholesterol, LDLDisease SusceptibilityFatty LiverFemaleHumansInsulinInsulin ResistanceNon-alcoholic Fatty Liver DiseaseObesityPolycystic Ovary SyndromeRisk FactorsTestosteroneYoung Adult

Pub Type(s)

Journal Article

Language

eng

PubMed ID

21898634

Citation

Zueff, L F N., et al. "Ultrasonographic and Laboratory Markers of Metabolic and Cardiovascular Disease Risk in Obese Women With Polycystic Ovary Syndrome." Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology, vol. 39, no. 3, 2012, pp. 341-7.
Zueff LF, Martins WP, Vieira CS, et al. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341-7.
Zueff, L. F., Martins, W. P., Vieira, C. S., & Ferriani, R. A. (2012). Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology, 39(3), 341-7. https://doi.org/10.1002/uog.10084
Zueff LF, et al. Ultrasonographic and Laboratory Markers of Metabolic and Cardiovascular Disease Risk in Obese Women With Polycystic Ovary Syndrome. Ultrasound Obstet Gynecol. 2012;39(3):341-7. PubMed PMID: 21898634.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. AU - Zueff,L F N, AU - Martins,W P, AU - Vieira,C S, AU - Ferriani,R A, Y1 - 2012/02/09/ PY - 2011/08/15/accepted PY - 2011/9/8/entrez PY - 2011/9/8/pubmed PY - 2012/8/9/medline SP - 341 EP - 7 JF - Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology JO - Ultrasound Obstet Gynecol VL - 39 IS - 3 N2 - OBJECTIVE: To evaluate whether the presence of polycystic ovary syndrome (PCOS) alters multiple ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women without any other health condition that could interfere with combined oral contraceptive (COC) eligibility criteria. METHODS: This was a case-control study evaluating 90 obese women (body mass index (BMI) ≥ 30.0 kg/m(2) and < 40 kg/m(2)) aged between 18 and 40 years without any other health condition that could interfere with COC eligibility criteria, of whom 45 had PCOS and 45 were age-matched controls. BMI, waist and hip circumference, arterial blood pressure, fasting insulin and glucose, quantitative insulin sensitivity check index (QUICKI), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglycerides, testosterone, sex hormone-binding globulin, free androgen index (FAI), carotid stiffness index, intima media thickness, flow-mediated dilatation (FMD) of the brachial artery and non-alcoholic fatty liver disease (NAFLD) were assessed. RESULTS: In women with PCOS, we observed a higher frequency of NAFLD (73.3 vs. 46.7%, P < 0.01) and higher FAI (10.4 vs. 6.8%, P < 0.01). We also observed a trend towards increased insulin levels (10.06 ± 6.66 vs. 7.45 ± 5.88 µIU/mL, P = 0.05), decreased QUICKI (0.36 ± 0.06 vs. 0.39 ± 0.07, P = 0.05) and decreased FMD (7.00 ± 3.87 vs. 8.41 ± 3.79%, P = 0.08). No other significant difference was observed. CONCLUSIONS: NAFLD is frequent in obese women without any other health condition that could interfere with COC eligibility criteria, especially in those with PCOS. This should be considered when choosing the best contraceptive option. SN - 1469-0705 UR - https://www.unboundmedicine.com/medline/citation/21898634/Ultrasonographic_and_laboratory_markers_of_metabolic_and_cardiovascular_disease_risk_in_obese_women_with_polycystic_ovary_syndrome_ L2 - https://doi.org/10.1002/uog.10084 DB - PRIME DP - Unbound Medicine ER -